Psychotic Disorders - Switzerland

Revenue in the Psychotic Disorders market is projected to reach US$72.03m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -0.67%, resulting in a market volume of US$69.67m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$602.10 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Switzerland is experiencing steady growth due to a combination of factors such as changing customer preferences, emerging trends in the market, local special circumstances, and underlying macroeconomic factors.Customer preferences in the Psychotic Disorders market in Switzerland are shifting towards more personalized and holistic treatment options. Patients are increasingly seeking treatments that not only address the symptoms of their condition but also take into account their overall well-being. This has led to a rise in demand for alternative therapies, such as cognitive behavioral therapy and mindfulness-based interventions, alongside traditional pharmaceutical treatments. Additionally, there is a growing emphasis on early intervention and prevention strategies, as patients and healthcare providers recognize the importance of early detection and treatment in improving long-term outcomes.Trends in the market are also contributing to the development of the Psychotic Disorders market in Switzerland. One notable trend is the increasing use of digital health technologies in the diagnosis and management of psychotic disorders. Mobile applications, wearable devices, and telehealth platforms are being utilized to monitor symptoms, provide psychoeducation, and facilitate remote consultations with healthcare professionals. This trend is driven by the desire for more accessible and convenient healthcare services, as well as the potential for improved patient engagement and outcomes.Local special circumstances in Switzerland further contribute to the growth of the Psychotic Disorders market. The country has a well-developed healthcare system with a strong emphasis on mental health services. There is a high level of awareness and understanding of psychotic disorders among healthcare professionals, which facilitates early detection and intervention. Additionally, Switzerland has a relatively high prevalence of psychotic disorders compared to other countries, which creates a significant market demand for treatments and services.Underlying macroeconomic factors also play a role in the development of the Psychotic Disorders market in Switzerland. The country has a stable and prosperous economy, which allows for investment in healthcare infrastructure and research and development. The Swiss government has implemented policies to support mental health services and promote the integration of mental health into primary care settings. These factors contribute to a favorable market environment for companies operating in the Psychotic Disorders market.In conclusion, the Psychotic Disorders market in Switzerland is experiencing growth due to changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors. The shift towards personalized and holistic treatment options, the use of digital health technologies, the well-developed healthcare system, and the stable economy all contribute to the development of the market.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.